Merck
  • Home
  • Search Results
  • Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Molecular cancer research : MCR (2014-12-31)
Koichi Okamoto, Aziz Zaanan, Hisato Kawakami, Shengbing Huang, Frank A Sinicrope
ABSTRACT

KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, was evaluated and found to potently induce Noxa, which was dependent upon c-Myc, and Bik. Isogenic mutant versus wild-type KRAS carcinoma cells showed elevated Bcl-xL, confirmed by KRAS siRNA or ectopic expression. Upregulated Bcl-xL by mutant KRAS was mediated by ERK as indicated by ERK knockdown. Bcl-xL expression was regulated at the level of mRNA and protein as shown using actinomycin D and cyclohexamide, respectively. Suppression of Bcl-xL by shRNA sensitized mutant KRAS cells to carfilzomib. Concurrent Bcl-xL antagonism by the BH3 mimetic ABT-263 combined with carfilzomib synergistically enhanced apoptosis that was dependent on Bax or p53, and was attenuated by Noxa or Bik shRNA. In support of this strategy, ectopically expressed Noxa enhanced apoptosis by ABT-263. Carfilzomib-induced Noxa and Bik sequestered Mcl-1 and ABT-263 released Bik and Bak from Bcl-xL, suggesting a mechanism for drug synergy. These preclinical findings establish mutant KRAS-mediated Bcl-xL upregulation as a key mechanism of apoptosis resistance in KRAS-mutant colorectal cancer. Furthermore, antagonizing Bcl-xL enabled carfilzomib-induced Noxa and Bik to induce synergistic apoptosis that reversed KRAS-mediated resistance. This novel study reveals a promising treatment strategy to overcome apoptosis resistance in KRAS-mutant colorectal cancer by concurrent upregulation of Noxa/Bik and antagonism of Bcl-xL.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, for molecular biology
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
塩化マグネシウム 溶液, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
塩化マグネシウム, anhydrous, ≥98%
Sigma-Aldrich
エチレンジアミン四酢酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
エチレンジアミン四酢酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
HEPES緩衝液, 1 M in H2O
Sigma-Aldrich
エチレンジアミン四酢酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
ジメチルスルホキシド, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
アクチノマイシンD, from Streptomyces sp., ~98% (HPLC)
Sigma-Aldrich
塩化マグネシウム 溶液, BioUltra, for molecular biology, ~1 M in H2O
Sigma-Aldrich
ジメチルスルホキシド, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
アクチノマイシンD, from Streptomyces sp., suitable for cell culture, ≥95%
SAFC
HEPES
Sigma-Aldrich
エチレンジアミン四酢酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
エチレンジアミン四酢酸, purified grade, ≥98.5%, powder
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
塩化マグネシウム, powder, <200 μm
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
ジメチルスルホキシド, PCR Reagent
Sigma-Aldrich
塩化マグネシウム 溶液, BioUltra, for molecular biology, 2 M in H2O
Sigma-Aldrich
エチレンジアミン四酢酸, 99.995% trace metals basis
SAFC
HEPES
Sigma-Aldrich
塩化マグネシウム, BioReagent, suitable for insect cell culture, ≥97.0%
Sigma-Aldrich
塩化マグネシウム 溶液, PCR Reagent, 25 mM MgCI2 solution for PCR